Agios Pharmaceuticals Inc. (AGIO)’s Financial Results Comparing With Eton Pharmaceuticals Inc. (NASDAQ:ETON)

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Eton Pharmaceuticals Inc. (NASDAQ:ETON) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agios Pharmaceuticals Inc. 38 -0.12 51.41M -5.99 0.00
Eton Pharmaceuticals Inc. 6 0.00 10.06M -2.36 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Agios Pharmaceuticals Inc. and Eton Pharmaceuticals Inc.

Profitability

Table 2 provides us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals Inc. 136,005,291.01% -48.2% -38.6%
Eton Pharmaceuticals Inc. 168,509,212.73% 0% -238.9%

Liquidity

Agios Pharmaceuticals Inc. has a Current Ratio of 6.9 and a Quick Ratio of 6.9. Competitively, Eton Pharmaceuticals Inc.’s Current Ratio is 5.9 and has 5.9 Quick Ratio. Agios Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Eton Pharmaceuticals Inc.

Analyst Recommendations

Ratings and Recommendations for Agios Pharmaceuticals Inc. and Eton Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agios Pharmaceuticals Inc. 0 0 1 3.00
Eton Pharmaceuticals Inc. 0 0 1 3.00

Agios Pharmaceuticals Inc.’s consensus price target is $45, while its potential upside is 36.86%. On the other hand, Eton Pharmaceuticals Inc.’s potential upside is 128.81% and its consensus price target is $13.5. Based on the analysts view we can conclude, Eton Pharmaceuticals Inc. is looking more favorable than Agios Pharmaceuticals Inc.

Insider and Institutional Ownership

The shares of both Agios Pharmaceuticals Inc. and Eton Pharmaceuticals Inc. are owned by institutional investors at 0% and 9.2% respectively. 0.3% are Agios Pharmaceuticals Inc.’s share owned by insiders. Competitively, 5.8% are Eton Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agios Pharmaceuticals Inc. 2.49% -2.96% -9.55% -6.82% -43.99% 4.34%
Eton Pharmaceuticals Inc. -2.56% -18.8% -17.7% -1.77% 0% -0.49%

For the past year Agios Pharmaceuticals Inc. has 4.34% stronger performance while Eton Pharmaceuticals Inc. has -0.49% weaker performance.

Summary

On 6 of the 11 factors Eton Pharmaceuticals Inc. beats Agios Pharmaceuticals Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.